Moreover, an antibody–drug conjugate combining the anti-CD26 monoclonal antibody YS110 with triptolide (Y-TR1) selectively targets CD26-positive cancer cells (malignant mesothelioma and leukemia), effectively inhibiting RNA polymerase II activity [1027]. Here, DPP4 is linked to malignant mesothelioma.